Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (GB:0HJ7)
LSE:0HJ7
0HJ7 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Atossa Therapeutics News
Bulls Say, Bears Say
Bulls Say
Efficacy And Safety ProfilePositive topline data from the KARISMA-Endoxifen Phase 2 study showed significant reduction in mammographic breast density, which was well tolerated.
Growth ProspectsConcerns are outweighed by growth prospects, as the market potential presents high rewards for the risks.
Strategic FocusThe company reiterated its strategic decision to focus its Z-endoxifen program on metastatic breast cancer, which is seen as a potentially more direct and quicker path to regulatory approval.
Bears Say
Adverse EventsDue to gynecological events observed at the 80 mg dose, the trial was amended to compare 40 mg Z-endoxifen + OFS to exemestane + OFS, using 4-week Ki-67 reduction as the primary endpoint.
Competitive LandscapeThe oral SERD space in second-line and beyond patients has become increasingly competitive, though to date, Phase 3 trials have only indicated a benefit in ESR1 mutant patients.
Options Prices
Currently, No data available
---
Ownership Overview
7.29% Insiders
8.05%
Mutual Funds
0.45% Other Institutional Investors
75.24% Public Companies and Individual Investors
0HJ7 FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Currently, no data Available
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 86 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on May 13, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.057 by $0.007.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Atossa Therapeutics have?
Currently, no data Available
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.057. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in GB:0HJ7
Atossa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.08 (― Downside)
$6.08 (― Downside)
Blogger Sentiment
Bullish
GB:0HJ7 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $16.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.20%
12-Months-Change
Fundamentals
Return on Equity
-34.87%
Trailing 12-Months
Asset Growth
-22.33%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
0HJ7 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.Read More>0HJ7 Stock 12 Month Forecast
Average Price Target
$6.08
Anixa Biosciences
―
Pliant Therapeutics
―
Senti Biosciences
―
Zura Bio
―
HilleVax, Inc
―